EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adaptive Biomarker‐Based Design for Early Phase Clinical Trials

Alessandra Serra iD, Gaëlle Saint-Hilary, Sandrine Guilleminot, Julia Geronimi, Pavel Mozgunov

Statistics in Medicine · 2025

DOI: 10.1002/sim.70275 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Statistics in Medicine, 2025. Verfasst von Alessandra Serra und 4 weiteren Autor:innen. Beteiligte Einrichtung: University of Cambridge, MRC Biostatistics Unit, Cambridge, UK. Hauptthemen laut MEDLINE: Research Design, Biomarkers, Clinical Trials as Topic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Identifying and quantifying predictive biomarkers is a critical issue of Precision Medicine approaches and patient‐centric clinical development strategies. Early phase adaptive designs can improve trial efficiency by allowing for adaptations during the course of the trial. In this work, we are interested in adaptations based on interim analysis permitting a refinement of the existing study population according to their predictive biomarkers. At an early stage, the goal is not to precisely define the target population, but to not miss an efficacy signal that might be limited to a biomarker subgroup. In this work, we propose a one‐arm two‐stage early phase biomarker‐guided design in the setting of an oncology trial where at the time of the interim analysis, several decisions can be made regarding stopping the entire trial early or continuing to recruit patients from the full or a selected patient population. Via simulations, we show that, although the sample size is limited, the proposed design leads to better decision‐making compared to a classical design that does not consider an enrichment expansion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Research DesignBiomarkersClinical Trials as TopicHumansComputer SimulationPrecision MedicineSample SizeModels, StatisticalBiomarkers, Tumor

Stichwörter der Autor:innen

continuous biomarkerearly phasepersonalized medicinepredictive

Substanzen

BiomarkersBiomarkers, Tumor

Autor:innen und Institutionen

  • University of Cambridge, MRC Biostatistics Unit, Cambridge, UK.
  • Department of Statistical Methodology, Saryga, France.
  • Translational Statistics Department, Institut de Recherches Internationales Servier, Gif-sur-Yvette, France.

ORCID-Profile: Alessandra Serra

Förderung

  • National Institute for Health and Care Research
  • Medical Research Council

Zitieren

APA

Serra, A., Saint-Hilary, G., Guilleminot, S., Geronimi, J., & Mozgunov, P. (2025). Adaptive Biomarker‐Based Design for Early Phase Clinical Trials. Statistics in Medicine. https://doi.org/10.1002/sim.70275

Vancouver

Serra A, Saint-Hilary G, Guilleminot S, Geronimi J, Mozgunov P. Adaptive Biomarker‐Based Design for Early Phase Clinical Trials. Statistics in Medicine. 2025. doi:10.1002/sim.70275

BibTeX
@article{Serra2025,
  author = {Serra, Alessandra and Saint-Hilary, Gaëlle and Guilleminot, Sandrine and Geronimi, Julia and Mozgunov, Pavel},
  title = {Adaptive Biomarker‐Based Design for Early Phase Clinical Trials},
  journal = {Statistics in Medicine},
  year = {2025},
  doi = {10.1002/sim.70275}
}
Kostenlos starten →